Mounjaro half-life chart: how tirzepatide behaves between doses

What a five-day half-life actually looks like across a week

A half-life is the time it takes for the concentration of a medicine in your body to fall by half. For tirzepatide, that figure sits at roughly five days, based on the pharmacokinetic data reviewed by the MHRA and summarised in the NHS tirzepatide medicines page. A once-weekly injection spaces doses seven days apart, so by the time you inject again, you still have a meaningful amount of the previous dose circulating. The result is a relatively smooth curve rather than a sharp rise and fall.

If you were to draw this as a simple tirzepatide half-life chart, you'd see the concentration peak in the day or two after each injection, dip gradually across the week, then rise again with the next dose. Over successive weeks those peaks and troughs narrow as the medicine accumulates toward a steady plateau. That plateau is what your prescriber is aiming for when they decide whether a dose increase is appropriate.

One practical check you can do in under a minute is to use our tirzepatide half-life calculator, which lets you enter your injection day and see how your drug levels are likely to look across the week. A day's drift here and there matters less with a five-day half-life than it would with a daily tablet, but keeping injection day consistent gives the cleanest drug-level pattern and makes any side-effect patterns easier for your prescriber to interpret.

Why steady state takes three to four weeks to arrive

Steady state is the point at which the amount of medicine entering your body each week roughly matches the amount your body clears. With a half-life of five days, full steady state takes four to five half-lives, somewhere between three and four weeks of weekly injections at the same dose. This is not a quirk of Mounjaro; it's a straightforward consequence of the pharmacokinetics, and it explains something patients often notice.

The first pen at a new dose can feel noticeably different from the third or fourth pen at the same dose. Appetite suppression, and sometimes nausea, may shift as blood levels stabilise. This is why the licensed schedule builds in at least four weeks at each dose level before any increase is considered. If you're curious about how the dose ladder maps onto this accumulation pattern, the Mounjaro dose chart lays out the full titration sequence clearly.

Steady state also matters for how you interpret early results. Weight change in week one reflects a fraction of the eventual steady-state exposure. Comparing your first week's appetite to week eight at the same dose is not comparing like for like, and your prescriber knows this when they review your progress at each stage.

What the half-life means when a dose is late or missed

Because tirzepatide clears slowly, a dose that's a day or two late does not immediately drop your level to zero. The curve descends gradually. That said, a late dose is not the same as a dose taken on time, and consistent delays across weeks can pull your average level lower than intended.

The Mounjaro Patient Information Leaflet sets out the specific guidance for missed doses, and your prescriber is the right person to advise you if your schedule has drifted significantly. What the half-life chart does not change is the recommendation to take each dose on the same day each week where possible. For a deeper look at how the pharmacokinetics translate into practical timing decisions, the full Mounjaro half-life guide covers this in detail.

One thing worth knowing: after stopping treatment entirely, tirzepatide's long half-life means it doesn't clear instantly. At five days per half-life, meaningful levels persist for several weeks after the last injection. This is relevant for anyone considering surgery or another medicine that might interact, and should always be discussed with the clinical team in advance. The NHS tirzepatide page includes a summary of interactions and situations where the timing of treatment matters.

How this applies to the decision about starting or continuing treatment

Understanding the half-life chart is genuinely useful background, but it's background, not a prescribing guide. The question of whether to start Mounjaro, which dose to begin at, when to titrate, and when to pause sits entirely with a qualified prescriber who has seen your full health picture. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside a qualifying condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. If you're wondering whether treatment could become a long-term part of your life, our page on Mounjaro for life covers what ongoing treatment looks like and what the evidence says about sustained use.

Cost is a real factor too. The Mounjaro cost page sets out what private treatment typically involves and what a legitimate price actually covers, which is worth reading before you compare quotes. If you'd like to explore whether tirzepatide could be appropriate for you, the tirzepatide overview gives the broader clinical picture, and our weight-loss treatments page walks through how a free consultation at nume works from first question to prescription. Every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated shortcut.